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ing in every HCV/HIV co-infected patient. Every LV dysfunction
suspicion should be conﬁrmed by echocardiographic.194 15th ICID Abstracts / International Journa
atabase (n=200) were 74%, 19.5% and 24.5%. Further studies to
larify the mechanism underlying the b12 resistance of CRF01 AE
iruses are ongoing.
Conclusion:Neutralization susceptibility of AE-Env is regulated
y the N-linked glycosylation sites, N186 and N197, in V2 and C2
egions cooperated with amino acid residue 185 in V2 region of
p120.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.764
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n search for a new anti-HIV-1 drug through inhibition of CA-
ypA interaction
. Verathamjamras1,∗, Y.-S. Tian2, T. Yasunaga3, T. Takagi2, N.
awashita2, M. Kameoka1
Thailand-Japan Research Collaboration Center on Emerging and Re-
merging Infections, Nonthaburi, Thailand
Graduate School of Pharmaceutical Sciences, Suita, Osaka, Japan
Genome Information Research Center, Research Institute for Micro-
ial Disease, Suita, Osaka, Japan
Background: Currently available antiretroviral drugs are clas-
iﬁed into 4 classes including reverse transcriptase inhibitors, pro-
ease inhibitors, integrase inhibitors and entry/fusion inhibitors.
ighly active antiretroviral therapy (HAART), using a combination
f three ormore antiretroviral drugs, canmanageHIV-1 replication
or many years; however, the virus tries to survive under antiretro-
iral therapy by mutate itself to become a drug-resistant variant.
herefore, the development of new classes of anti-HIV-1 drugs
ith different inhibition mechanisms is required. The interaction
etweenHIV-1 capsidprotein (CA) andhumancyclophilinA (CypA)
s crucial for HIV-1 life cycle. Although the role of CypA in HIV-1 life
ycle remains unclear, CA-CypA interaction is an interesting target
or the development of new anti-HIV-1 agents.
Methods: Seventy-seven compounds which could bind to CA
n silico were tested for its activity against HIV-1 replication. Each
ompoundwas tested in vitroat aﬁxconcentrationusingavesicular
tomatitis virus G protein (VSVG)-pseudotyped, luciferase reporter
IV-1 in the 1st round screening. The compounds that showed
otent HIV-1 inhibition were evaluated for dose-dependent effect
nd cytotoxicity effect in the 2ndround screening.
Results: Eleven compounds showed a potent inhibitory effect
n HIV-1 replication in the 1st round screening. Five compounds
ere considered to be safe and potent HIV-1 inhibitors in the 2nd
ound screening.
Conclusion: Although most compounds had little or no effect
n HIV-1 replication, ﬁve compounds showed a potent inhibitory
ctivity on viral replication through our screening. Further studies
n their inhibitory mechanisms are underway.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.765fectious Diseases 16S (2012) e158–e316
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HCV co-infection may promote the subclinical left ventricular
dysfunction development in HIV-infected subjects
M. Dabrowska, T. Mikula, A. Wiercinska-Drapalo ∗
Warsaw Medical University, Warsaw, Poland
Background:ChronicHCV infectionmaybe linkedwithpossible
myocarditis and cardiomyopathy development. The pathophysiol-
ogy of cardiac injury in hepatitis C is still unknown, however it
seems that inﬂammation and apoptosis may play a crucial role in
this progressive process. The brain natriuretic peptide (BNP) is a
hormone secreted predominantly from the cardiac ventricles on
response to increased wall stress, wall distension and stretching
or neurohormonal activation. Presently, BNP is commonly used
as a sensitive biomarker of subclinical/clinical left ventricular (LV)
dysfunction.
The present study aimed to compare BNP serum levels in HIV-
infected and HCV/HIV co-infected subjects with or without ARV
therapy.
Methods: Eighty HIV-infected patients (65 males, 15 females,
mean age 40 years; 29 with HCV co-infection, 48 on cART) were
included to the cross-sectional study. Compensated liver cirrhosis
was diagnosed clinically in 9 (11%) studied subjects, all of them
had HCV/HIV co-infection. One HCV/HIV co-infected subject had
conﬁrmed right ventricular dysfunction diagnosis. The BNP serum
levels were evaluated by ELISA. A BNP cut-off level for heart fail-
ure diagnosis was 100 pg/mL as in immunocompetent population.
In statistical analyses U Mann-Whitney, Spearman correlation and
chi2 tests were used. P <0.05 was considered statistically signiﬁ-
cant.
Results: Seventy eight (97.5%) studied subjects had BNP con-
centration above 42 fmol/L (100 pg/mL), 7 patients (8.7%) had
concentration above 168 fmol/L (400 pg/mL) which is associated
with a worse outcome. There was no difference in mean BNP
serum levels inARV-treated anduntreatedpatients (106.2±94.5 vs
116.4±87.9 fmol/L; p =0.15). However, the mean BNP serum level
was signiﬁcantly higher in HCV/HIV co-infected in comparison to
HIV mono-infected patients (160.0±130.9 vs 81.9±37.2 fmol/L;
p <0.0001). There was no relationship between BNP serum levels
and HIV viral load, CD4 cell count, gender and ABC or PIs use.
Conclusion: HCV co-infection may signiﬁcantly enhance the
risk of the subclinical LV dysfunction in HIV-infected subjects.
The ARV therapy probably does not reduce progressive myocardial
damage in this group of patients. We suggest regular BNP screen-http://dx.doi.org/10.1016/j.ijid.2012.05.766
